Göcze P, Vahrson H
Szülészeti és Nögyógyászati Klinika, Pécsi Orvostudományi Egyetem.
Orv Hetil. 1992 Dec 13;133(50):3191-4.
The serum concentrations of squamous cell carcinoma antigen (SCC) were determined in 59 patients with invasive carcinoma of the uterine cervix, in 21 patients with benign cervical diseases. Pretherapeutic SCC levels were elevated (> 2.5 ng/ml) in 63% (34/54) of the patients with squamous cervical carcinoma. 5 patients with adenomatosus cervical carcinoma had not elevated levels. In 21 patients with benign cervical diseases, 4.8% (1/21) of SCC values were above the normal range. There were no correlation of SCC levels and the degree of the histological differentiation or clinical stages. Serial SCC determinations revealed a correlation with the clinical course of disease in 72.2% (26/36) with squamous cervical carcinoma. Rising levels were always associated with progression. The SCC level increased before clinical signs of progression with a median lead time of 3 months. Patients with cervical adenocarcinoma for follow up CA 125 determination was recommended. The determination of SCC is a useful tool checking the patients, detecting early progression of squamous cervical tumor.
对59例浸润性宫颈癌患者和21例宫颈良性疾病患者测定了血清鳞状细胞癌抗原（SCC）浓度。鳞状宫颈癌患者中63%（34/54）的治疗前SCC水平升高（>2.5 ng/ml）。5例宫颈腺癌患者的SCC水平未升高。在21例宫颈良性疾病患者中，4.8%（1/21）的SCC值高于正常范围。SCC水平与组织学分化程度或临床分期无相关性。连续测定SCC显示，72.2%（26/36）的鳞状宫颈癌患者的SCC水平与疾病临床进程相关。SCC水平升高总是与病情进展相关。SCC水平在出现临床进展迹象前升高，中位提前期为3个月。建议对宫颈腺癌患者进行CA 125随访测定。SCC测定是检查患者、检测鳞状宫颈癌早期进展的有用工具。
